Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.21), $0.16 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $3.4 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.